Clinical Trial: Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks
Study Status: Withdrawn
Recruit Status: Unknown status
Study Type: Interventional
Official Title: OCT, Visual Outcome and Angiographic Analysis of Choroidal Neovascularization in Six Eyes With Angioid Streaks Treated With a Single Intravitreal Injection of Bevacizumab
Brief Summary: Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks
Detailed Summary: A consecutive case series of patients with angioid streaks that developed subfoveal choroidal neovascularization were treated with a primary 2.5 mg injection of Bevacizumab (Avastin) intravitreally. All patients were evaluated with BCVA at 1, 2 , 4 and 12 weeks and OCT and fluoresceine angiography at month 1 and 3. (Patients will be follow 6 months)
Sponsor: Asociación para Evitar la Ceguera en México
Current Primary Outcome:
- BCVA
- Fluoresceine Angiography
- Optical Coherence Tomography
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Asociación para Evitar la Ceguera en México
Dates:
Date Received: June 30, 2006
Date Started: November 2005
Date Completion: May 2006
Last Updated: January 23, 2008
Last Verified: January 2008
